Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Trial Profile

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs GR MD 02 (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2017 According to a Galectin Therapeutics media release, recruitment of this trial has been slowed significantly due to changes in the standard of care for metastatic melanoma (i.e., approval of KEYTRUDA),
    • 07 Feb 2017 Data from this trial presented at the 9th GTCBio Immunotherapeutics & Immunomonitoring Conference, according to a Galectin Therapeutics media release.
    • 07 Feb 2017 Interim results published in the Galectin Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top